A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Multiple Myeloma (MM)Cancer
Interventions
DRUG

ABBV-467

Intravenous (IV) Infusion

Trial Locations (24)

3004

Alfred Health /ID# 214665, Melbourne

3065

St Vincent's Hospital Melbourne /ID# 222066, Fitzroy

5000

Royal Adelaide Hospital /ID# 223354, Adelaide

6000

Royal Perth Hospital /ID# 225498, Perth

6009

Perth Blood Institute Ltd /ID# 226650, Nedlands

10002

National Taiwan University Hospital /ID# 209322, Taipei City

28027

CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 214739, Madrid

28040

Hospital Universitario Fundacion Jimenez Diaz /ID# 214672, Madrid

29010

Hospital Universitario Virgen de la Victoria /ID# 214756, Málaga

31008

CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 217170, Pamplona

40447

China Medical University Hosp /ID# 209323, Taichung

44000

CHU de Nantes, Hotel Dieu -HME /ID# 215480, Nantes

91010

City of Hope /ID# 209786, Duarte

94000

Hopital Henri Mondor /ID# 214588, Créteil

5239424

Sheba Medical Center /ID# 214065, Ramat Gan

85719-1478

University of Arizona Cancer Center - North Campus /ID# 219102, Tucson

07601

Hackensack Univ Med Ctr /ID# 221035, Hackensack

02903-4923

Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418, Providence

29605-4255

Prisma Health Cancer Institute-Faris Road /ID# 219076, Greenville

467-8602

Nagoya City University Hospital /ID# 214696, Nagoya

277-8577

National Cancer Center Hospital East /ID# 214697, Kashiwa-shi

812-8582

Kyushu University Hospital /ID# 220800, Fukuoka

104-0045

National Cancer Center Hospital /ID# 214801, Chuo-ku

08035

Hospital Universitario Vall d'Hebron /ID# 214690, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY